Intermittent Oro-esophageal Tube on Rehabilitation Therapy Compliance in Stroke Patients
Launched by ZENG CHANGHAO · Mar 1, 2024
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how different methods of providing nutrition affect the rehabilitation of stroke patients. Specifically, it compares two types of feeding tubes: an Intermittent Oro-esophageal Tube and a Nasogastric Tube. By participating in this trial, patients will help researchers understand which method helps them stick to their rehabilitation therapy better.
To be eligible for the trial, participants must be at least 18 years old, have been diagnosed with stroke, and have difficulty swallowing, which is known as dysphagia. They should also be stable and able to cooperate with assessments. If enrolled, patients will receive regular rehabilitation treatment alongside their specific nutrition method for the duration of the study. This trial is currently not recruiting, but it aims to gather important information that could improve care for stroke patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age ≥ 18 years;
- • meeting the diagnostic criteria of stroke;
- • any degree of dysphagia at admission;
- • steady vital signs, without severe cognitive impairment or sensory aphasia, able to cooperate with the assessment.
- • transferred out within three weeks of hospitalization in the neurology department.
- Exclusion Criteria:
- • complicated with other neurological diseases;
- • damaged mucosa or incomplete structure in nasopharynx;
- • tracheostomy tube plugged;
- • unfeasible to the support of parenteral nutrition;
- • simultaneously suffering from liver, kidney failure, tumors, or hematological diseases.
About Zeng Changhao
Zeng Changhao is a dedicated clinical trial sponsor focused on advancing medical research and innovation through rigorous and ethically conducted clinical studies. With a commitment to improving patient outcomes, Zeng Changhao collaborates with leading healthcare professionals and research institutions to explore novel therapies and treatment modalities. The organization emphasizes transparency, compliance, and patient safety, ensuring that all trials adhere to the highest regulatory standards. Through its strategic partnerships and a patient-centric approach, Zeng Changhao aims to contribute significantly to the development of effective and safe healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhengzhou, Henan, China
Patients applied
Trial Officials
Nieto Luis, Master
Study Director
Site Coordinator of United Medical Group located in Miami
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported